Yüklüyor......
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy; approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2. These recurrent mutations in key metabolic enzymes lead to the production of the oncometabolite 2-hydroxyglutarate, whi...
Kaydedildi:
| Yayımlandı: | Blood Cancer J |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8175383/ https://ncbi.nlm.nih.gov/pubmed/34083508 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00497-1 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|